Combination of Dasatinib and Peg-Interferon Alpha 2b in First Line for Chronic Myeloid Leukemia in Chronic Phase
Status:
Completed
Trial end date:
2018-10-31
Target enrollment:
Participant gender:
Summary
Interferon alpha was a therapy used in Chronic Myeloid Leukemia in Chronic phase prior to the
advent of tyrosine kinase inhibitors. Synergistic effect of the combination of Peg-IFNα2a
with Imatinib was demonstrated in the clinical SPIRIT trial. In this study, the investigators
address the question of the efficacy and safety of dasatinib in combination with low dose of
Peg-IFNα-2b as frontline therapy for patients with newly diagnosed Chronic Myeloid Leukemia
in Chronic phase.